Board of Directors of the Company in its meeting held on Tuesday, 12th August, 2025 at 3:00 P.M at the corporate office of the company situated at 703, Arunachal Building, 19, Barakhamba ....
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) reported virtually no business activity for Q1 FY26, with total income of just Rs 0.40 lakh compared to Rs 4.77 lakh in the same quarter last year. Net sales from operations appear to be zero, as the company's drug manufacturing operations remain suspended pending renewal of its licences with the FDA in Panchkula. The company continues to incur costs (employee expenses of Rs 13.16 lakh, depreciation of Rs 3.67 lakh, other expenses of Rs 6.03 lakh), resulting in a loss before tax of Rs 22.87 lakh and a loss for the period of Rs 22.01 lakh (EPS of Rs -0.12). The auditor (Nemani Garg Agarwal & Co.) issued a Qualified Conclusion, flagging missing share certificates for an investment of Rs 53.80 lakh and a stalled capital work-in-progress of Rs 2.91 crore, and also drew an Emphasis of Matter on the absence of revenue from operations. The company has unpaid BSE listing fees for four years, with action already initiated by the exchange.
This is a deeply negative filing for shareholders — operations are halted, revenue has collapsed, losses continue to mount, the auditor has qualified the results with an emphasis of matter, and there is no clear timeline for when the business will restart. The stock is likely to remain under pressure and carries significant going-concern risk until the manufacturing licence is renewed and operations resume.